This section contains letters that have been sent or received by AABB on issues of concern to the transfusion medicine and cellular therapies communities.
Letter From Boston Medical Center Commending AABB Members and the NBE for Providing Assistance After the Boston Marathon Bombings - 5/1/13 (PDF) Letter to CDER in Response to Class-Wide Label Change for Skin Antiseptic Products Containing Alcohol - 1/10/13Letter to Congress Supporting Legislation to Allow for More Reasonable Proficiency Testing Referral Penalties - 10/3/12Letter to Congress Supporting Bill to Expand Requirements to Report Studies to Clinicaltials.gov - 10/3/12Letter to IRS Regarding Medical Device Excise Tax - 8/20/12FDA Response to AABB TTD Request for Review of Blood Relative vs. First Degree Relative in CJD Screening - 4/20/12 (PDF)Memo to Members Regarding AABB’s Transfusion Medicine and Cellular Therapy Initiatives – 3/8/12Letter to The Joint Commission Regarding Proposed Blood Transfusion Service and Donor Center Standards – 10/22/10Letter From U.S. Rep. Van Hollen Urging CDC to Enhance Collaboration with Private Sector on Hemovigilance – 7/21/10 (PDF)Letter to Congress Calling for Maintenance of Funding for Vector-Borne Diseases Program at CDC – 4/9/10Memo to Members Regarding Technical Correction to the Circular of Information for the Use of Human Blood and Blood Components (August 2009) – 12/22/09AABB Asks Test Manufacturers to Bring Additional HTLV–I/II Tests to the U.S. Market – 8/31/09 (PDF)Letter to Facilities with ISBT 128 Variance – 7/16/09Letter to Facilities with ISBT 128 Status Unknown – 7/16/09Letter from CMS Clarifying MUE Policy – 4/14/09 (PDF)Letter to HRSA on Specifications for Accreditation of Cord Blood Banks – 4/10/09Response from the National Quality Forum Regarding the Definition of a Transfusion–Related Event – 3/5/09 (PDF)Letter to the National Quality Forum Regarding the Definition of a Transfusion–Related Event – 2/12/09Letter to FDA from the AABB Ad Hoc Task Force to Propose an Alternate Post–Market Study Design for Seven–Day Platelets – 4/28/08FDA Response to Letter from AABB Bacterial Contamination Standard Task Force to FDA on Approval Strategies for Point–of–Release Testing for Bacterial Contamination – 4/24/08 (PDF)Letter to the FDA Nominating Industry Representatives to BPAC – 2/28/08Letter to the FDA on a Draft Template for a Shorter Inter–donation Interval During an Influenza Pandemic – 2/14/08Follow up to the Letter from AABB Bacterial Contamination Standard Task Force to Gambro BCT and Fenwal in Response to the Discontinuation of the Passport Study – 2/13/08Letter to FACT Proposing Accreditation Partnership – 2/4/08Letter from AABB Bacterial Contamination Standard Task Force to Gambro BCT and Fenwal in Response to the Discontinuation of the Passport Study – 1/31/08Letter from AABB Bacterial Contamination Standard Task Force to FDA on Approval Strategies for Point–of–Release Testing for Bacterial Contamination – 12/26/07Letter to the AMA on Cord Blood Banking – 11/16/07Letter to Verax Biomedical, Inc. Regarding the Platelet PGD® Test – 10/3/07 (PDF)Letter to HHS on the Appointment of the Advisory Council on Blood Stem Cell Transplantation – 10/2/07Letter to CMS Requesting Proper Categorization of the eBDS Test System – 9/14/07Letter to FDA in Response to the Report of the Human Tissue Task Force – 7/6/07Letter to Facilities Selected for Inclusion in 2007 NBCUS – 3/7/07 (PDF)